Cidara Therapeutics at the Evercore HealthCONx Conference
Recently, Cidara Therapeutics, Inc. (NASDAQ: CDTX), a leading biotechnology company recognized for its unique Cloudbreak platform, announced its participation in the renowned Evercore 7th Annual HealthCONx Conference. This event serves as a crucial platform for healthcare leaders to share insights and direct discussions about advancements in biopharmaceuticals.
Event Participation Details
Jeffrey Stein, Ph.D., the President and CEO of Cidara, will be engaging in a fireside chat scheduled for early December. This conversation will provide insights into Cidara's innovative approach to drug development, particular emphasis will be placed on how their drug-Fc conjugate (DFC) immunotherapies can positively impact patient care.
Event Schedule
Event: Evercore 7th Annual HealthCONx Conference
Date: Tuesday in December
Time: 7:55 AM ET
Format: Fireside Chat
Webcast: Click on the link to access the event: Webcast Link
Insights into Cidara's Innovations
Cidara Therapeutics is making significant strides with its Cloudbreak platform, designed to produce DFCs that consist of small molecules or peptides coupled with a human antibody fragment (Fc). One of Cidara's lead DFC candidates is CD388, a long-acting antiviral aimed at providing universal prevention against influenza strains. This candidate is aimed at transforming the treatment landscape, offering potential one-dose protection against seasonal and pandemic influenza.
Recent Achievements
Recently, CD388 received a Fast Track Designation from the U.S. FDA, a testament to its promising capability in improving public health. This development highlights Cidara’s commitment to tackling health challenges with innovative solutions. Additionally, the company is embarking on a Phase 2b clinical trial that shows their momentum in research and development.
Future Initiatives and Investor Interaction
Besides the conference presentation, Cidara will facilitate one-on-one investor meetings during the event. Interested investors are encouraged to reach out to their Evercore representatives to set up discussions. Engaging with investors is a vital aspect of maintaining transparency and driving the company's growth forward.
Company's Vision
Cidara Therapeutics does not solely focus on antiviral development. They are also expanding their portfolio into oncology. In July, they received Investigational New Drug (IND) clearance for CBO421, a DFC aimed at targeting CD73 on solid tumors. This advancement underlines Cidara’s versatility and ambition in addressing various serious diseases.
About Cidara Therapeutics
Based in San Diego, California, Cidara Therapeutics is committed to delivering effective therapies through its Cloudbreak platform. For additional details about their projects, including updates, and for information on their lead candidates, you can visit their website for further exploration: Cidara Therapeutics Website.
Contact Information
Investor Contact:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
Media Contact:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
Frequently Asked Questions
What is the focus of Cidara Therapeutics?
Cidara Therapeutics focuses on developing innovative immunotherapy treatments using their Cloudbreak platform, especially for serious diseases.
Who is presenting at the Evercore Conference?
Jeffrey Stein, Ph.D., the President and CEO, will represent Cidara Therapeutics at the conference.
What is CD388?
CD388 is Cidara's lead candidate, a long-acting antiviral designed for the universal prevention of influenza.
What recent recognition did Cidara receive?
CD388 was granted Fast Track Designation by the U.S. FDA, highlighting its importance in combating influenza.
How can investors connect with Cidara Therapeutics?
Investors interested in connecting with Cidara during the conference should contact their Evercore representatives directly.
